Clinical Trials

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07101328 2026-05-13

BAF_FRontier-1

215 enrolled

Phase NA Not yet recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07558057 2026-04-30

COGNITOX

Not yet recruiting

225 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Marginal Zone

NCT07476378 2026-03-17

Archonc-001

69 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07424833 2026-02-20

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

180 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07376330 2026-02-12

Molecular and Cellular Characterization of MALT Lymphoma

Not yet recruiting

400 enrolled

Phase NA Not yet recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07299331 2025-12-23

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

50 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

15 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07144657 2025-08-27

GastricMALToma

40 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Not yet recruiting

200 enrolled